PBA
BCYC

Paradigm Biocapital Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Paradigm Biocapital Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,246,759
Closed -$80.8M – 38
2024
Q1 		$80.8M Sell
3,246,759
-460,242
-12% -$9.78M 2.85% 18
2023
Q4 		$67M Buy
3,707,001
+64,694
+2% +$1.07M 3.14% 14
2023
Q3 		$73.2M Buy
3,642,307
+1,656,877
+83% +$37.9M 4.97% 6
2023
Q2 		$50.7M Buy
1,985,430
+168,649
+9% +$3.92M 3.92% 13
2023
Q1 		$38.6M Buy
1,816,781
+583,501
+47% +$14.6M 3.66% 15
2022
Q4 		$36.5M Buy
1,233,280
+74,594
+6% +$2M 4.29% 13
2022
Q3 		$27M Buy
1,158,686
+110,170
+11% +$2.62M 3.59% 13
2022
Q2 		$17.6M Buy
+1,048,516
New +$22.1M 3.51% 11

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Paradigm Biocapital Advisors's BCYC Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Bicycle Therapeutics (BCYC) in Q2 2024, closing a stake of 3,246,759 shares — an estimated $80.8M sold.

Paradigm Biocapital Advisors first reported a position in BCYC in Q2 2022 and held it in 8 quarters. The position peaked at $80.8M in Q1 2024. 107 funds tracked by Wall St. Rank hold BCYC as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Bicycle Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 3,246,759 Bicycle Therapeutics shares in Q2 2024, an estimated $80.8M.
  • Paradigm Biocapital Advisors first reported a position in Bicycle Therapeutics in Q2 2022 and held it in 8 quarters.
  • Paradigm Biocapital Advisors's Bicycle Therapeutics position peaked at $80.8M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.